The Global Fund's leadership on harm reduction: 2002-2009
- PMID: 20171865
- DOI: 10.1016/j.drugpo.2010.01.002
The Global Fund's leadership on harm reduction: 2002-2009
Abstract
Injecting drug use is a major driver of the HIV epidemic globally. Whilst robust evidence points to the effectiveness of harm reduction programmes to halt and reverse injecting drug use driven epidemics, uptake of these programmes in developing and transitional countries has been slow. In part, this slow uptake stems from inadequate financial resources for harm reduction; legal, socio-cultural and medical barriers leading to stigmatisation; and weak health systems unequipped to manage marginalized groups. The Global Fund to Fight AIDS, Tuberculosis and Malaria, established in 2002, has become the major multilateral source of external funding for harm reduction programmes in countries experiencing concentrated HIV epidemics driven by injecting drug use. Between 2004 to end of 2008, the Global Fund invested around US$180 million in harm reduction programmes in 42 countries. This funding has helped to initiate and scale up harm reduction programmes in settings where domestic funding was lacking. In addition to financing harm reduction programmes globally, the Global Fund has stimulated a strong dialogue between vulnerable groups and governments. Furthermore, the Global Fund has engaged in a dialogue with countries to encourage an evidence-based approach to policy-making that recognizes the immense value of harm reduction in HIV prevention and control.
Copyright (c) 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Global Fund investments in harm reduction from 2002 to 2009.Int J Drug Policy. 2012 Jul;23(4):279-85. doi: 10.1016/j.drugpo.2012.01.013. Epub 2012 Mar 13. Int J Drug Policy. 2012. PMID: 22421551
-
How much will it cost? Estimation of resource needs and availability for HIV prevention, treatment and care for people who inject drugs in Asia.Int J Drug Policy. 2010 Mar;21(2):107-9. doi: 10.1016/j.drugpo.2009.11.004. Epub 2010 Feb 9. Int J Drug Policy. 2010. PMID: 20144859
-
Islam and harm reduction.Int J Drug Policy. 2010 Mar;21(2):115-8. doi: 10.1016/j.drugpo.2009.11.003. Epub 2009 Dec 16. Int J Drug Policy. 2010. PMID: 20006483
-
Increasing prevalence of HIV, and persistent high-risk behaviours among drug users in Bangladesh: need for a comprehensive harm reduction programme.Drug Alcohol Rev. 2007 Jul;26(4):445-54. doi: 10.1080/09595230701373925. Drug Alcohol Rev. 2007. PMID: 17564883 Review.
-
'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.Addiction. 2008 Jan;103(1):137-45. doi: 10.1111/j.1360-0443.2007.02053.x. Epub 2007 Nov 20. Addiction. 2008. PMID: 18028519 Review.
Cited by
-
Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine.Cost Eff Resour Alloc. 2014 Nov 24;12:25. doi: 10.1186/1478-7547-12-25. eCollection 2014. Cost Eff Resour Alloc. 2014. PMID: 25873788 Free PMC article.
-
Human Rights and the Global Fund to Fight AIDS, Tuberculosis and Malaria: How Does a Large Funder of Basic Health Services Meet the Challenge of Rights-Based Programs?Health Hum Rights. 2017 Dec;19(2):183-195. Health Hum Rights. 2017. PMID: 29302175 Free PMC article.
-
Public health and international drug policy.Lancet. 2016 Apr 2;387(10026):1427-1480. doi: 10.1016/S0140-6736(16)00619-X. Epub 2016 Mar 24. Lancet. 2016. PMID: 27021149 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical